Statins and portal hypertension: A new pharmacological challenge

Current Vascular Pharmacology

Volumn 10, Issue 6, 2012, Pages 767-772

  Ramírez, Gonzalo ^a   Briceño, Jimmy ^a   Rojas, Armando ^a  

^a UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

Author keywords

Hepatic stellate cell; Intrahepatic vascular resistance; Liver cirrhosis; Portal hypertension; Statins; Vascular endothelium

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATORVASTATIN; CAVEOLIN 1; CHOLESTEROL; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; EXTRACELLULAR SUPEROXIDE DISMUTASE; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHO KINASE; SIMVASTATIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; XANTHINE OXIDASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; HYPEREMIA; LIVER CIRRHOSIS; LIVER FIBROSIS; MICROCIRCULATION; OXIDATIVE STRESS; PORTAL HYPERTENSION; PROTEIN EXPRESSION; STELLATE CELL; VARICOSIS;

ANIMALS; ENDOTHELIAL CELLS; HEPATIC STELLATE CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PORTAL; INFLAMMATION MEDIATORS; NITRIC OXIDE; OXIDATIVE STRESS; PORTAL PRESSURE;

EID: 84870186648     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112803520918     Document Type: Article

References (79)

1. Cichoz-Lach H, Celiáski K, Somka M, et al. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008; 59 (Suppl 2): 231-8.
2. Sorensen H, Thulstrup AM, Mellemkjar L, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 2003; 56: 88-93.
3. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
4. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009; 15: 479-89.
5. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, et al. Current concept on the pathophysiology of portal hypertension. Ann Hepatol 2007; 6: 28-36.
6. Bosch J, Abraldes J, Fernandez M, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: New target in the treatment of portal hypertension. J Hepatol 2010; 23: 558-67.
7. Shibayama Y, Nakata K. Significance of septal fibrosis for disturbance of hepatic circulation. Liver 1992; 12: 22-5.
8. Kawada N, Tran-Thi T, Klein H, et al. The contraction of hepatic stellate cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815-23.
9. Zhang J, Pegoli W, Clemens M. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994; 266: 624-32.
10. Harrison D. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
11. Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-31.
12. Bellis L, Berzigotti A, Abraldes J, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003; 37: 378-84.
13. Shah V, Toruner M, Haddad F, et al. Impaired Endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-8.
14. Rockey D, Chung J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-51.
15. Morales-Ruiz M, Cejudo-Martin P, Fernández-Varo G, et al Transduction of the liver with activated akt normalizes portal pressure in cirrhosis. Gastroenterology 2003; 125: 522-31.
16. Minshall R, Sessa W, Stan R. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003; 285: 1179-83.
17. Isshiki M, Ying Y, Fujita T, et al. A molecular sensor detects signal transduction from caveolae in living cells. J Biol Chem 2002; 277: 43389-98.
18. Ghosh S, Gachhui R, Crooks C, et al. Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase. Consequences for catalysis. J Biol Chem 1998; 273: 22267-71.
19. Gratton JP, Bernatchez P, Sessa W. Caveolae and caveolins in the cardiovascular system. Circ Res 2004; 94: 1408-17.
20. Bist A, Fielding P, Fielding C. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Cell Biol 1997; 94: 10693-8.
21. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 45: 242-53.
22. Rikitake Y, Liao J. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-5.
23. Parola M, Robina G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-6.
24. Heistad DD. Oxidative stress and vascular disease: 2005 Duff Lecture. Arterioscler Thromb Vasc Biol 2006; 26: 689-95.
25. Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, et al. Increased Oxidative Stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008; 47: 1248-56.
26. Rojas A, Figueroa H, Morales MA, et al. Facing Up the ROS labyrinth-Where to go? Curr Vasc Pharmacol 2006; 4: 277-89.
27. De Minics S, Brenner D. NOX in liver fibrosis. Arch Biochem Biophys 2007; 462: 266-77.
28. Rojas A, Figueroa H, Re L, et al. Oxidative Stress at vascular wall. Mechanistic and pharmacological aspect. Arch Med Res 2006; 37: 436-48
29. Adam O, Laufs U. Antioxidative effects of statins. Arch Toxicol 2008; 82: 885-92.
30. Graupera M, García-Pagán J, Parés M, et al Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 2003; 39: 515-24.
31. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-kinase signaling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006; 55: 1296-05.
32. Marra F. Pinzani M. Role of hepatic stellate cells in the pathogenesis of portal hypertension. Nefrología 2002; 22 (Suppl 5): 34-40.
33. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993; 328:1828-35.
34. Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liverspecific paricytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642-6.
35. Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histological progression. Gastroenterology 1982; 83: 777-85.
36. Rockey C, Weisiger R. Endothelin induces contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-40.
37. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lipocytes: the principal collagen producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681-5.
38. Loreal O, Clement B, Schuppan D, et al. Distribution and cellular origin of collagen VI during development and in cirrhosis. Gastroenterology 1992; 102: 980-7.
39. Maher JJ, Friedman SL, Roll FJ, et al. Inmunolocalization of laminin in normal rat liver and biosynthesis of laminin by hepatic lipocytes in primary culture. Gastroenterology 1988; 94: 1053-152.
40. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5
41. Yin M, Wheele MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 177: 942-52.
42. Thimgan M, Yee H. Quantitation of rat hepatic stellate cell contraction: Stellate cells contribution to sinusoidal resistance. Am J Physiol 1999; 277: 137-43.
43. Stephenson K, Harvey SA, Mustafa SB, et al. Endothelin association with the cultured rat Kupffer cell: characterization and regulation. Hepatology 1995; 22: 896-5.
44. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci USA 1993; 90: 9266-70.
45. Reynaert H, Thompson Mg, Thomas T, et al. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-81.
46. Bataller R, Nicolas JM, Ginees P, et al. Contraction of human hepatic stellate cells activated in culture: a role of voltage-operated calcium channels. J Hepatol 1998; 29: 398-408.
47. Saab S, Tam S, Tran BN, et al. Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1. J Biomed Sci 2002; 9: 607-12.
48. Soon R, Yee H. Stellate cell contraction: Role, regulation, and potential therapeutic target. Clin Liver Dis 2008; 12: 791-803.
49. Melton Ac, Datta A, Yee HF Jr. Ca+2 independent contractile force generation by rat hepatic stellate cells in response to endothelin-1. Am J Physiol Gastrointest Liver Physiol 2006; 290: 7-13.
50. Yee HF. Rho directs activation-associated changes in rat hepatic stellate cell morphology via regulation of the actin cytoskeleton. Hepatology 1998; 28: 843-50.
51. Kawada N, Seki S, Kuroki T, et al. ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem Biophys Res Commun 1999; 266: 296-300.
52. Kamath P, Carpenter H, Loyd R, et al. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl 2000; 6: 596-602.
53. Moller S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995; 23: 135-44.
54. Moore K, Wendon J, Frazer M, et al. Plasma endothelin inmunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774-8.
55. Malek AM, Greene AL, Inzumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci USA 1993; 90: 5999-6003.
56. Yoshizumi M, Kurihara H, Morita T, et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 1990; 166: 324-9.
57. Rieder H, Ramadori G, Meyer KH. Sinusoidal endothelial liver cells in vitro release endothelin-augmentation by transforming growth factor beta and Kupffer cell-conditioned media. Klin Wochenschr 1991; 69: 387-91.
58. Tran Duc AT, Schwab AJ, Simard A, et al. Reduction in hepatic endothelin-1 clearance in cirrhosis. Clin Sci 2003; 105: 227-34.
59. Gondo K, Ueno T, Sakamoto M, et al. The endothelin-1 binding site in rat liver tissue: light and electro-microscopic autoradiographic studies. Gastroenterology 1993; 104: 1745-9.
60. Housset C, Rocket DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Porc Natl Acad Sci USA 1993:90: 9266-70.
61. Rockey DC, Fouassier L, Chung J, et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998; 27: 472-80.
62. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009; 25:1995-2005.
63. Abraldes J, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-8.
64. Abraldes J, Rodríguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-6.
65. Rikitake Y, Liao JK. Rho GTPases, Statins, and Nitric Oxide. Circ Res 2005; 97: 1232-5.
66. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
67. Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rhokinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-47.
68. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutarylcoenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
69. Garcia-Cardena G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998; 392: 821-4.
70. Hattori Y, Nakanishi N, Akimoto S, et al. HMG-CoA Reductase inhibitor increases GTP cyclohydrolase i mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 176-82.
71. Hernández-Perera O, Pérez D, Navarro J, et al. Effects of the 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
72. Hernández O, Pérez D, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 29: 616-22.
73. Wassman S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin ii mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and RAC1 GTPase. Mol Pharmacol 2001; 59: 646-54.
74. Yoshida M, Sawada T, Ishii H, et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro involvement of rho gtpasedependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21: 1165-71.
75. Lucey M, Mathurin P, Morgan T. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-69.
76. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. Simvastatin modulates TNF-induced adhesion molecules expression in human endothelial cells. Life Sci 2004; 75: 1287-302.
77. Moreno M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009; 296: 147-56.
78. Weitz G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
79. Greenwood J, Mason J. Satins and the vascular endothelial inflammatory response. Trends Immunol 2007; 28: 88-98.